Literature DB >> 30173825

Transplanting the pulmonary virome: Dynamics of transient populations.

Alicia B Mitchell1, Bassel Mourad2, Lucy C Morgan3, Brian G G Oliver2, Allan R Glanville4.   

Abstract

BACKGROUND: Lung transplantation provides a unique opportunity to investigate the dynamics of the human pulmonary virome that is transplanted within the donor lungs. The pulmonary virome comprises both "resident" and "transient" viruses. In this study we aimed to analyze the dynamics of the "transient" members.
METHODS: We conducted a single-center, prospective, longitudinal investigation of community-acquired respiratory viruses detected in nasopharyngeal swabs, swabs of explanted and donor lungs, and serial bronchoalveolar lavages post-transplant.
RESULTS: Fifty-two consecutive lung transplant recipients were recruited (bilateral:heart‒lung:bilateral lung-liver = 48:2:2) (age [mean ± SD] 48 ± 15 years, range 20 to 63 years; 27 males and 25 females). Follow-up was 344 ± 120 (range 186 to 534) days. Seventeen of 45 explanted lungs were positive for influenza A and/or B (A = 14, B = 2, A+B = 1), despite recipient vaccination and negative nasal swabs, and 4 of 45 had human rhinovirus and 2 of 45 parainfluenza. Donor swabs showed influenza (A = 1, B = 1) and rhinovirus (n = 3). Day 1 lavage showed influenza A (n = 28), rhinovirus (n = 9), and parainfluenza (n = 1). Forty-seven of 52 recipients had a positive lavage for virus (38 of 47 on multiple lavages). Influenza persisted for 59 ± 38 (range 4 to 147) days in 27 of 52, and 14 had a single isolate. Rhinovirus persisted for 95 ± 84 (range 22 to 174) days in 13 of 52, and 13 had a single isolate. Analysis of 118 paired transbronchial biopsies and lavage demonstrated no association between viruses and acute cellular rejection (Fisher's exact test, 2 tailed, p = 1.00).
CONCLUSIONS: Using a sensitive uniplex polymerase chain reaction we found that the transplanted pulmonary virome often includes community-acquired respiratory viruses, including influenza, which are variably persistent but not associated with acute rejection.
Copyright © 2018 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic lung allograft dysfunction; community-acquired respiratory viruses; lung transplantation; microbiome; respiratory virome

Mesh:

Year:  2018        PMID: 30173825     DOI: 10.1016/j.healun.2018.06.002

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  5 in total

1.  Metagenomic sequencing reveals time, host, and body compartment-specific viral dynamics after lung transplantation.

Authors:  Stefanie Widder; Irene Görzer; Benjamin Friedel; Nina Rahimi; Stefan Schwarz; Peter Jaksch; Sylvia Knapp; Elisabeth Puchhammer-Stöckl
Journal:  Microbiome       Date:  2022-04-23       Impact factor: 16.837

Review 2.  The respiratory microbiome after lung transplantation: Reflection or driver of respiratory disease?

Authors:  Caroline C Eskind; Meghan H Shilts; Ciara M Shaver; Suman R Das; Gowri Satyanarayana
Journal:  Am J Transplant       Date:  2021-04-16       Impact factor: 8.086

Review 3.  The lung microbiome in lung transplantation.

Authors:  John E McGinniss; Samantha A Whiteside; Aurea Simon-Soro; Joshua M Diamond; Jason D Christie; Fredrick D Bushman; Ronald G Collman
Journal:  J Heart Lung Transplant       Date:  2021-05-07       Impact factor: 13.569

4.  Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients.

Authors:  Auke E S de Zwart; Annelies Riezebos-Brilman; Jan-Willem C Alffenaar; Edwin R van den Heuvel; Christiaan Tji Gan; Wim van der Bij; Huib A M Kerstjens; Erik A M Verschuuren
Journal:  Am J Transplant       Date:  2020-06-17       Impact factor: 8.086

Review 5.  The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.